Ligand Pharma(LGND)
$298.71+4.90 (+1.67%)
LGND
Ligand Pharma financials statements
$298.71
At close:+4.90 (+1.67%)
Want to see LGND full AI Analyst Report?
Ligand Pharma (LGND) Ratios
860 Followers
Ligand Pharma Ratios
LGND's free cash flow for Q3 2026 was $-27.73M. For the 2026 fiscal year, LGND's free cash flow was decreased by $-142.00K and operating cash flow was $-27.59M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 22.23 | 8.93 | 14.15 | 2.67 | 11.15 |
| Quick Ratio | 21.98 | 8.55 | 12.72 | 2.53 | 10.50 |
| Cash Ratio | 4.67 | 1.95 | 1.37 | 0.46 | 0.47 |
| Solvency Ratio | 0.29 | 0.28 | 1.03 | 0.06 | 0.23 |
| Operating Cash Flow Ratio | 1.32 | 2.61 | 2.95 | 1.40 | 1.89 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 1.80 | 0.00 |
| Net Current Asset Value | $ 288.85M | $ 220.22M | $ 151.13M | $ 98.42M | $ -11.68M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.29 | 0.01 | 0.01 | 0.12 | 0.25 |
| Debt-to-Equity Ratio | 0.44 | 0.01 | 0.01 | 0.15 | 0.40 |
| Debt-to-Capital Ratio | 0.31 | 0.01 | 0.01 | 0.13 | 0.28 |
| Long-Term Debt-to-Capital Ratio | 0.30 | 0.00 | 0.00 | 0.00 | 0.28 |
| Financial Leverage Ratio | 1.53 | 1.13 | 1.12 | 1.28 | 1.58 |
| Debt Service Coverage Ratio | 33.56 | 11.28 | 138.71 | 0.51 | 7.49 |
| Interest Coverage Ratio | 10.01 | -7.44 | 18.20 | 1.69 | 5.29 |
| Debt to Market Cap | 0.12 | 0.00 | 0.00 | 0.07 | 0.12 |
| Interest Debt Per Share | 23.59 | 0.55 | 0.39 | 5.31 | 20.69 |
| Net Debt to EBITDA | 1.43 | -1.60 | -0.17 | 0.53 | 2.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 97.54% | 93.37% | 73.31% | 73.08% | 74.26% |
| EBIT Margin | 59.29% | 3.32% | 48.98% | 19.27% | 38.02% |
| EBITDA Margin | 71.89% | 24.41% | 76.79% | 41.38% | 59.11% |
| Operating Profit Margin | 17.61% | -13.53% | 9.09% | 1.55% | 42.99% |
| Pretax Profit Margin | 59.29% | 1.51% | 48.48% | 18.35% | 29.89% |
| Net Profit Margin | 46.42% | -2.41% | 39.72% | -17.00% | 23.66% |
| Continuous Operations Profit Margin | 46.42% | -2.41% | 40.98% | -2.66% | 31.61% |
| Net Income Per EBT | 78.29% | -160.13% | 81.93% | -92.64% | 79.13% |
| EBT Per EBIT | 336.79% | -11.14% | 533.08% | 1185.74% | 69.53% |
| Return on Assets (ROA) | 7.97% | -0.43% | 6.63% | -4.37% | 4.40% |
| Return on Equity (ROE) | 12.23% | -0.49% | 7.44% | -5.58% | 6.96% |
| Return on Capital Employed (ROCE) | 3.10% | -2.50% | 1.55% | 0.46% | 8.27% |
| Return on Invested Capital (ROIC) | 2.42% | 4.00% | 1.31% | -0.06% | 8.26% |
| Return on Tangible Assets | 12.00% | -0.71% | 13.57% | -10.96% | 7.10% |
| Earnings Yield | 3.40% | -0.21% | 4.22% | -2.96% | 2.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.39 | 3.94 | 3.34 | 5.60 | 2.64 |
| Payables Turnover | 2.03 | 2.12 | 14.44 | 9.95 | 7.40 |
| Inventory Turnover | 0.72 | 0.78 | 1.46 | 3.97 | 2.28 |
| Fixed Asset Turnover | 24.84 | 6.74 | 5.24 | 7.14 | 7.41 |
| Asset Turnover | 0.17 | 0.18 | 0.17 | 0.26 | 0.19 |
| Working Capital Turnover Ratio | 0.49 | 0.65 | 0.68 | 0.67 | 0.59 |
| Cash Conversion Cycle | 409.36 | 385.42 | 333.61 | 120.35 | 249.57 |
| Days of Sales Outstanding | 83.12 | 92.70 | 109.27 | 65.17 | 138.49 |
| Days of Inventory Outstanding | 505.65 | 465.20 | 249.61 | 91.85 | 160.42 |
| Days of Payables Outstanding | 179.41 | 172.48 | 25.27 | 36.67 | 49.33 |
| Operating Cycle | 588.77 | 557.90 | 358.88 | 157.02 | 298.90 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.55 | 5.31 | 2.87 | 8.17 | 4.74 |
| Free Cash Flow Per Share | 2.53 | 4.23 | -0.25 | 7.11 | 4.21 |
| Dividend Paid and CapEx Coverage Ratio | 109.20 | 4.94 | 0.92 | 7.69 | 8.99 |
| Capital Expenditure Coverage Ratio | 109.20 | 4.94 | 0.92 | 7.69 | 8.99 |
| Operating Cash Flow Coverage Ratio | 0.11 | 13.66 | 8.04 | 1.57 | 0.24 |
| Operating Cash Flow to Sales Ratio | 0.18 | 0.58 | 0.38 | 0.70 | 0.33 |
| Free Cash Flow Yield | 1.34% | 3.95% | -0.35% | 10.64% | 2.73% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 29.36 | -487.05 | 23.69 | -33.78 | 44.96 |
| Price-to-Sales (P/S) Ratio | 13.64 | 11.73 | 9.41 | 5.74 | 10.63 |
| Price-to-Book (P/B) Ratio | 3.59 | 2.36 | 1.76 | 1.89 | 3.13 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 74.76 | 25.32 | -289.19 | 9.40 | 36.68 |
| Price-to-Operating Cash Flow Ratio | 74.07 | 20.19 | 24.92 | 8.17 | 32.60 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 4.54 | -0.09 | 0.21 | -0.02 |
| Enterprise Value Multiple | 20.41 | 46.44 | 12.09 | 14.40 | 20.13 |
| Enterprise Value | 3.93B | 1.89B | 1.22B | 1.17B | 2.87B |
| EV to EBITDA | 20.41 | 46.44 | 12.09 | 14.40 | 20.13 |
| EV to Sales | 14.67 | 11.34 | 9.28 | 5.96 | 11.90 |
| EV to Free Cash Flow | 80.41 | 24.48 | -285.26 | 9.75 | 41.03 |
| EV to Operating Cash Flow | 79.68 | 19.52 | 24.58 | 8.48 | 36.47 |
| Tangible Book Value Per Share | 25.51 | 25.07 | 17.22 | 8.25 | 19.76 |
| Shareholders’ Equity Per Share | 52.60 | 45.40 | 40.52 | 35.42 | 49.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.22 | 2.60 | 0.15 | 1.14 | -0.06 |
| Revenue Per Share | 13.86 | 9.14 | 7.59 | 11.63 | 14.52 |
| Net Income Per Share | 6.44 | -0.22 | 3.02 | -1.98 | 3.44 |
| Tax Burden | 0.78 | -1.60 | 0.82 | -0.93 | 0.79 |
| Interest Burden | 1.00 | 0.45 | 0.99 | 0.95 | 0.79 |
| Research & Development to Revenue | 0.30 | 0.13 | 0.19 | 0.18 | 0.13 |
| SG&A to Revenue | 0.34 | 0.47 | 0.40 | 0.36 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.25 | 0.20 | 0.31 | 0.16 |
| Income Quality | 0.40 | -24.07 | 0.95 | -4.13 | 1.38 |
Currency in USD

